Press Release: TrialTrove Data Shows Australia is Open for Business says Avance Clinical at BIO Digital 2020
June 10, 2020
Adelaide, Australia – The leading Australian CRO for biotechs, Avance Clinical announced at BIO Digital today that Australia currently has 2,413 trials planned or ongoing.
Importantly in Australia, despite the global COVID-19 pandemic, no healthy volunteer studies have been suspended, and only 27 Phase 1 or 2 studies were temporarily put on hold for various reasons (TrialTrove, 9 June 2020).
The leading Australian CRO for biotechs, Avance Clinical announced at BIO Digital today that Australia currently has 2,413 trials planned or ongoing.
Importantly in Australia, despite the global
COVID-19 pandemic, no healthy volunteer studies have been suspended, and only
27 Phase 1 or 2 studies were temporarily put on hold for various reasons
(TrialTrove, 9 June 2020).
Avance Clinical commended the
Australian industry for exceptional COVID-19 management which has meant
Australia leads the world in maintaining clinical trials business as usual.
Avance Clinical’s Chief Strategy
Officer, Ben Edwards presented at BIO Digital 2020 today on the many benefits of
running trials in Australia.
of our work is supporting small to medium-sized biotechnology companies
executing Phase 1 and Phase 2 trials. Our client base currently extends across
North America, Canada, New Zealand, Europe and Asia.
Australia is a
well-established location for international clinical trials and our management
of the COVID-19 crisis has made it an even more attractive trials destination.”
Avance Clinical is a medium-sized
full-service CRO known for its nimble and collaborative approach, with more
than 20-years of experience in managing early phase trials.
In addition to the impressive COVID-19
management, a key factor in sponsor demand is the speed, access to high quality
sites and attractive cost of running trials in Australia including:
Australian Government financial rebate of 43.5% on clinical trial spend
required for clinical trials and streamlined regulatory processes
medical, research and scientific community, leading investigators and
KOLs, and modern medical facilities
Australia’s reputation for FDA
compliant scientific and research excellence, its advanced healthcare, and the
opportunity to access patients in a less clinical trial competitive environment
further reinforces its advantage as a destination for clinical trials.
Avance Clinical has more than 20-years of experience and is now one of
Australia’s leading Contract Research Organisations. Avance Clinical facilitates
quality drug development by aligning people, skills, and expertise in the
pursuit of drug development for a healthier world.
Clinical is committed to providing high-quality clinical research services with
its highly-experienced team.
collective pool of knowledge and experience at Avance Clinical continually
grows through the careful selection of experts who also demonstrate passion in their
Clinical offers high quality services in an established clinical trial ecosystem,
that includes world-class Investigators and Sites able to access specialised
patient groups. Other benefits include:
Government R&D grant means up to 43.5% rebate on clinical trial spend
pivot during COVID-19 pandemic – speed and continuity
Initiation Visit (SIV) and Study Start achieved in 5 – 6
required for clinical trials
material is not mandated for Phase I clinical trials
clinical trial environment with world-class Investigators and sites
healthy subject databases and specialised patient populations
Phase 1 facilities across Australia including hospital-based units for
hospitals with world class infrastructures and dedicated Clinical Trial
Units with a long track-record in FDA compliant research
studies: Northern hemisphere Sponsors can conduct their studies year-round
by taking advantage of Australia’s counter-flu and allergy seasons